Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
07 August 2025 | Story Martinette Brits | Photo Stephen Collett
Prof Willem Boshoff
Prof Willem Boshoff shares insights from decades of rust disease research during his inaugural lecture at the University of the Free State.

Rust diseases of food crops remain one of agriculture’s most enduring and evolving challenges. In his inaugural lecture on 23 July 2025 at the University of the Free State (UFS), Prof Willem Boshoff shared how these complex pathogens continue to pose a significant threat to South Africa’s staple crops – and why continued research is more critical than ever.

Titled Battling rust diseases of food crops in South Africa, the lecture reflected on decades of rust research and recent developments in pathogen virulence. Prof Boshoff, from the Department of Plant Sciences, emphasised that the threat posed by rust fungi today stems from their “mechanisms of variability, their ease of long-distance spore dispersal, and subsequent foreign race incursions”.

 

A shifting disease landscape

Rust fungi are biotrophic organisms that cannot be cultured on artificial growth media. This makes rust research a technically demanding field that requires living pathogen collections, seed sources, skilled researchers, and specialised infrastructure. Prof Boshoff noted that for more than 35 years, the UFS has been at the forefront of this work, monitoring rust pathogens on wheat, barley, oats, maize, and sunflower.

While wheat remains the most extensively studied type, recent rust outbreaks across a range of crops point to a worrying trend. A localised outbreak of stem rust on spring wheat in the Western Cape has been linked to race BFGSF, which carries a previously unknown combination of virulence genes affecting both wheat and triticale. In 2021, leaf rust race CNPSK was detected, showing virulence to the highly effective Lr9 resistance gene.

More recently, stripe rust race 142E30A+ – first reported in Zimbabwe – was found in wheat cultivars from the Free State and northern irrigation areas. “Results revealed increased susceptibility of especially spring irrigation wheat cultivars,” Prof Boshoff explained, particularly due to its virulence to the Yr9 and Yr27 resistance genes.

Rust pathogens affecting other crops are also evolving. In maize, only a few lines with mostly stacked resistance gene combinations were effective against all tested isolates. In sunflower, just four of 30 Agricultural Research Council national trial hybrids showed resistance to local rust races.

 

Building better resistance

A key strategy in rust control lies in identifying and understanding resistance in host plants. This, Prof Boshoff stressed, requires optimised phenotyping systems for both greenhouse and field conditions, along with a solid understanding of available resistance sources. At the UFS, several recent studies have contributed valuable data to both local and international plant breeding programmes.

“Continued local and regional rust research is critical,” he said. “It supports early detection of new races, alerts to producers through updated cultivar responses, and enables efficient breeding strategies and other sustainable methods of rust management.”

The rust programme at the UFS has not only supported varietal release and on-farm risk management, but also strengthened collaboration between plant scientists, industry partners, and international researchers. With South Africa’s strategic location and history of rust surveillance, the programme continues to play a pivotal role in continental and global food security efforts.

 

About Prof Willem Boshoff

Prof Willem Boshoff is a plant pathologist with a strong background in wheat breeding and rust disease control. He holds four degrees from the University of the Free State, all awarded cum laude: a BScAgric (1994), BScAgric Honours (1995), MScAgric (1997), and PhDAgric (2001). His doctoral research focused on the control of foliar rusts in wheat.

Between 2001 and 2016, he worked as a wheat breeder and contributed to the release of several commercial cultivars. He joined the UFS Department of Plant Sciences in 2017 and has since been actively involved in national and international research projects, capacity development, and advancing disease resistance in food crops.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept